MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Abbott Laboratories

Slēgts

SektorsVeselības aprūpe

132.08 0.37

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

129.76

Max

132.11

Galvenie mērījumi

By Trading Economics

Ienākumi

7.6B

9.2B

Pārdošana

339M

11B

P/E

Sektora vidējais

17.363

63.778

EPS

1.34

Dividenžu ienesīgums

1.78

Peļņas marža

84.099

Darbinieki

114,000

EBITDA

82M

3B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+6.47% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

1.78%

2.39%

Nākamie ieņēmumi

2025. g. 16. apr.

Nākamais dividenžu datums

2025. g. 15. maijs

Nākamais Ex dividenžu datums

2025. g. 15. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

7.8B

230B

Iepriekšējā atvēršanas cena

131.71

Iepriekšējā slēgšanas cena

132.08

Ziņu noskaņojums

By Acuity

27%

73%

81 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Abbott Laboratories Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 22. janv. 19:03 UTC

Peļņas

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

2025. g. 22. janv. 18:20 UTC

Peļņas

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

2025. g. 22. janv. 12:45 UTC

Peļņas

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

2024. g. 1. nov. 14:15 UTC

Galvenie tirgus virzītāji

Reckitt, Abbott Shares Rise After Baby-Formula Lawsuit Win -- Update

2024. g. 1. nov. 10:10 UTC

Galvenie tirgus virzītāji

Reckitt Shares Surge After Baby Formula Lawsuit Win

2024. g. 31. okt. 23:57 UTC

Karstas akcijas

Stocks to Watch: Intel, Amazon.com, Abbott Laboratories, MasTec

2024. g. 31. okt. 23:14 UTC

Galvenie tirgus virzītāji

Abbott Laboratories Shares Rise After Baby-Formula Verdict

2024. g. 16. okt. 12:03 UTC

Peļņas

Abbott Laboratories 3Q Sales Top Expectations

2025. g. 1. febr. 18:14 UTC

Top Ziņas

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

2025. g. 22. janv. 16:40 UTC

Top Ziņas
Peļņas

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

2025. g. 22. janv. 15:20 UTC

Peļņas

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

2025. g. 22. janv. 15:08 UTC

Peļņas

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

2025. g. 22. janv. 13:51 UTC

Peļņas

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

2025. g. 22. janv. 13:39 UTC

Top Ziņas
Peļņas

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

2025. g. 22. janv. 12:02 UTC

Peļņas

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

2025. g. 22. janv. 12:01 UTC

Peļņas

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

2025. g. 22. janv. 12:01 UTC

Peļņas

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

2025. g. 22. janv. 12:00 UTC

Peļņas

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

2025. g. 22. janv. 12:00 UTC

Peļņas

Abbott Labs 4Q Net $9.23B >ABT

2025. g. 22. janv. 12:00 UTC

Peļņas

Abbott Labs 4Q Sales $10.97B >ABT

2025. g. 22. janv. 12:00 UTC

Peļņas

Abbott Labs 4Q Organic Sales Growth Up 8.8% >ABT

2025. g. 22. janv. 12:00 UTC

Peļņas

Abbott Labs 4Q EPS $5.27 >ABT

2025. g. 22. janv. 12:00 UTC

Peļņas

Abbott Labs 4Q Adj EPS $1.34 >ABT

2025. g. 22. janv. 09:54 UTC

Karstas akcijas

Stocks to Watch Wednesday: Netflix, Oracle, Trump Media, Softbank -- WSJ

2024. g. 1. nov. 17:33 UTC

Tirgus saruna

Abbott's Baby-Formula Lawsuit Win Could Decrease Liabilities -- Market Talk

2024. g. 16. okt. 14:21 UTC

Top Ziņas
Peļņas

Abbott Posts Solid Quarter. The Stock Is Rising. -- Barrons.com

2024. g. 16. okt. 12:25 UTC

Peļņas

Abbott Labs Beats Q3 Sales And Earnings Expectations, Raises Full-Year Outlook -- MarketWatch

2024. g. 16. okt. 12:02 UTC

Top Ziņas
Peļņas

Abbott Posts Solid Quarter. That Wasn't Enough to Lift Shares. -- Barrons.com

2024. g. 16. okt. 11:59 UTC

Peļņas

Abbott Earnings Edge Past Q3 Views, Led By Medical Devices -- IBD

2024. g. 16. okt. 11:37 UTC

Peļņas

Abbott Labs Sees 4Q Adj EPS $1.31-Adj EPS $1.37 >ABT

Salīdzinājums

Cenas izmaiņa

Abbott Laboratories Prognoze

Cenas mērķis

By TipRanks

6.47% augšup

Prognoze 12 mēnešiem

Vidējais 140.21 USD  6.47%

Augstākais 158 USD

Zemākais 117 USD

Pamatojoties uz 16 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Abbott Laboratories — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

16 ratings

14

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

126.3 / 133.46Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

81 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.